American Society of Gene and Cell Therapy (2014). Commercialization of gene and cell therapy products program. Available at www.asgct.org/meetings-educational-programs/asgct-annual-meetings/2014-annual-meeting/attendee/program-submission/commercialization-workshop-schedule (accessed Feb.6, 2014).
2.
BioMarin Pharmaceutical (2014a). BioMarin announces FDA approval for VIMIZIM™ (elosulfase alfa) for the treatment of patients with Morquio A Syndrome. Available at http://investors.bmrn.com/releasedetail.cfm?ReleaseID=825970 (accessed March6, 2014).
3.
BioMarin Pharmaceutical (2014b). BioMarin receives positive opinion from the CHMP in the European Union for VIMIZIM™ (elosulfase alfa) for Morquio A Syndrome. Available at http://investors.bmrn.com/releasedetail.cfm?ReleaseID=827132 (accessed March6, 2014).
4.
DalzellStewart (2014). Order filed March 5, 2014, in Trustees of the University of Pennsylvania, plaintiff, v. St. Jude's Children's Research Hospital, defendant, and Juno Therapeutics, intervenor. U.S. District Court, Eastern District of Pennsylvania. Available via PACER at https://ecf.paed.uscourts.gov/doc1/153113436130 (accessed March7, 2014).
5.
DavilaM.L., RiviereI., WangX., et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 224–225. Available at http://stm.sciencemag.org/content/6/224/224ra25 (accessed March7, 2014).
6.
Memorial Sloan-Kettering Cancer Center (2014). Cell therapy shows remarkable ability to eradicate cancer in clinical study. Available at www.mskcc.org/pressroom/press/cell-therapy-shows-remarkable-ability-eradicate-clinical-study (accessed March7, 2014).
7.
Servier (2014). Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors. Available at www.servier.com/content/cellectis-and-servier-announce-collaboration-allogeneic-cell-therapy-ucart19-treat-leukemia (accessed March6, 2014).
8.
U.S. Food and Drug Administration (2014). FDA approves Vimizim to treat rare congenital enzyme disorder. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386008.htm (accessed March6, 2014).
9.
Voyager Therapeutics (2014). Third Rock Ventures launches Voyager Therapeutics with $45 million series A to develop life-changing gene therapies for CNS disorders. Available at www.voyagertherapeutics.com/pdfs/Voyager_02.11.14.pdf (accessed March3, 2014).
